NCT03453528View on ClinicalTrials.gov

Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

NACompletedINTERVENTIONAL

Enrollment

1,225

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

December 4, 2024

Study Completion Date

January 3, 2025

Conditions

Prostate-specific Membrane AntigenmCRPC or Advanced/Metastatic Solid Tumors

Interventions

DRUG

68Ga-PSMA

68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).

Trial Locations (1)

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola

All Listed Sponsors

lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER

NCT03453528 - Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors | Biotech Hunter | Biotech Hunter